Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma

NCT04059562 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Cholangiocarcinoma

Interventions

COMBINATION_PRODUCT: Combination of Lonsurf® and Irinotecan

Sponsor

Heinrich-Heine University, Duesseldorf

Collaborators

[object Object]